Dr Luskin on Pediatric-Inspired Regimens for Adolescents and Young Adults With ALL

These are chemotherapy regimens that are based on multiple treatment phases, including an induction phase, a consolidation phase that includes specific treatment for the central nervous system, and a maintenance phase. Many of the drugs used in these regimens are similar to those used in adult protocols; however, there is a greater emphasis on agents such as vincristine and corticosteroids, as well as asparaginase, which is a unique drug. Asparaginase depletes plasma asparagine, an amino acid. Normal cells are generally able to tolerate this depletion because they can synthesize asparagine on their own and continue to function.

Marlise Rachael Luskin, MD, MSCE, associate program director of the Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the Adult Leukemia Program, reviewed the rationale and practical considerations for using pediatric-inspired regimens in adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), highlighting how these approaches have reshaped outcomes in this population.

According to Luskin, pediatric-inspired regimens are best understood as multi-phase chemotherapy programs that mirror the structure and intensity of pediatric ALL protocols. These regimens include a clearly defined induction phase, consolidation and intensification phases, central nervous system–directed therapy, and a prolonged maintenance phase. While many of the cytotoxic agents used overlap with those in adult ALL regimens, the dosing, scheduling, and emphasis on certain agents differ in clinically meaningful ways.

A central component distinguishing pediatric-inspired regimens is the prominent role of asparaginase, an enzyme-based therapy that depletes circulating asparagine, an amino acid critical for leukemic lymphoblast survival. Luskin explained that normal cells can compensate for asparagine depletion by synthesizing the amino acid endogenously, whereas ALL cells lack this capacity and undergo selective cell death. This biologic vulnerability underpins the substantial efficacy of asparaginase-containing regimens in younger patients.

However, Luskin emphasized that asparaginase introduces a unique toxicity profile that requires careful monitoring, particularly in AYA patients. These toxicities differ from the myelosuppression that typically dominates adult chemotherapy management and include metabolic and coagulation-related complications such as hyperglycemia, hypertriglyceridemia, hepatic dysfunction, and an increased risk of thrombosis. Older AYA patients are especially susceptible to these adverse effects compared with younger pediatric patients.

Despite these challenges, Luskin noted that extensive experience from pediatric oncology has generated well-established strategies to mitigate and manage asparaginase-related toxicities. Structured monitoring protocols, proactive supportive care measures, and multidisciplinary involvement—including pharmacists and advanced practice providers—are essential to safely delivering these regimens. She highlighted that a growing body of reference guidelines, reviews, and educational resources has helped adult oncology teams become more comfortable administering pediatric-inspired therapy.

Importantly, Luskin underscored that the improved survival outcomes observed in AYA patients treated with pediatric-inspired regimens justify the additional complexity of care. Multiple studies have demonstrated superior remission rates and long-term survival in this age group compared with historical adult ALL regimens, leading many centers to adopt these approaches as a standard for fit AYA patients.